Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 17/20 | 0.67 |
| ▸ | WNT1 | P04628 | 10/20 | 0.67 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | CLK3 | P49761 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27201494 | 0.89 | DYRK1A (0.56) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL30834135 | 0.89 | DYRK1A (0.56) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL27201421 | 0.88 | DYRK1A (0.50) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL27201435 | 0.84 | DYRK1A (0.64) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL27201490 | 0.81 | MAP4K4 (0.44) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL17095563 | 0.80 | DYRK1A (1.00) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL27201264 | 0.79 | GSK3B (0.56) | DYRK1AGSK3BKCNH2 | |
| SCHEMBL30885290 | 0.79 | PRKD3 (0.45) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL27201439 | 0.79 | PRKD3 (0.45) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL27201338 | 0.79 | DYRK1A (0.61) | DYRK1AWNT1CLK2CLK3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | DYRK1A 2404/4885WNT1 689/4885CLK2 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.